Tetraphase Pharmaceuticals Stock Price Up 13% Following Analyst Upgrade (TTPH)
Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) shot up 13% during trading on Wednesday after JMP Securities raised their price target on the stock from $16.00 to $20.00, American Banking & Market News reports. JMP Securities currently has an outperform rating on the stock. Tetraphase Pharmaceuticals traded as high as $15.24 and last traded at $14.78, with a volume of 1,196,067 shares trading hands. The stock had previously closed at $13.08.
TTPH has been the subject of a number of other recent research reports. Analysts at Brean Capital initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, July 8th. They set a “buy” rating and a $23.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 20th. Finally, analysts at Gabelli initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Friday, June 20th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $19.25.
In other Tetraphase Pharmaceuticals news, Insider Guy Macdonald sold 10,000 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $11.59, for a total value of $115,900.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
The stock’s 50-day moving average is $11.38 and its 200-day moving average is $11.41. The company’s market cap is $384.1 million.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by $0.17. The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $2.79 million. On average, analysts predict that Tetraphase Pharmaceuticals will post $-2.27 earnings per share for the current fiscal year.
Tetraphase Pharmaceuticals, Inc, incorporated on July 7, 2006, is a clinical stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.